The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the World Health Organisation, as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines, alongside key delivery partner UNICEF, on Wednesday published COVAX’s first interim distribution forecast.
Building on the publication of the 2021 COVAX global and regional supply forecast, the interim distribution forecast provides information on early projected availability of doses of the Pfizer/BioNTech vaccine in Q1 2021 and the AstraZeneca/Oxford vaccine candidate in first half 2021 to COVAX Facility participants.
This announcement comes less than two weeks after the announcement of the signed advance purchase agreement with Pfizer/BioNTech and a little more than a month after the first COVID-19 vaccine received WHO EU approval.
The purpose of sharing the interim distribution with countries, even in today’s highly dynamic global supply environment, is to provide governments and health systems with the information they need to plan for their national vaccination programmes, WHO says.
Final allocations will be published in due course.
The interim distribution forecast outlines projected delivery of vaccine doses to all Facility participants, with the exception of participants who have either exercised their rights to opt-out, have not submitted vaccine requests, or have not yet been allocated doses.